Home Newsfeeds MoffettNathanson Downgrades DXC Technology to Underperform, Lowers Price Target to $28

MoffettNathanson Downgrades DXC Technology to Underperform, Lowers Price Target to $28

MoffettNathanson analyst Lisa Ellis downgrades DXC Technology (NYSE:DXC) from Market Perform to Underperform and lowers the price target from $32 to $28.

byBenzinga Newsdesk

January 19, 2023

1 minute read

MoffettNathanson analyst Lisa Ellis downgrades DXC Technology (NYSE:DXC) from Market Perform to Underperform and lowers the price target from $32 to $28.

Alembic Global Downgrades Albany Intl to Neutral

By Benzinga Newsdesk

August 16, 12:11 PM

Alembic Global analyst Peter Skibitski downgrades Albany Intl (NYSE:AIN) from Overweight to Neutral.

AIN

News

WidePoint Launches Secure Technology Asset Management Solution

By Benzinga Newsdesk

August 31, 9:27 AM

FAIRFAX, VA / ACCESSWIRE / August 31, 2022 / WidePoint Corporation(NYSE:WYY), the innovative technology Managed Solution Provider (MSP) specializing in Identity and Access Management (IAM), Telecommunications and

WYY

Summit Therapeutics Ivonescimab In Combination with Chemotherapy Approved In China By NMPA For 2L+ EGFRm NSCLC Based On HARMONi-A Clinical Trial; Clinically Meaningful Efficacy Observed In Overall Survival Towards Ivonescimab Plus Chemotherapy; Shares…

By Benzinga Newsdesk

May 31, 10:04 PM

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46For Subset of Patients Previously Receiving 3rd Generation

SMMT